Consortium of Experts

About Us

We have assembled a consortium of pharmaceutical, medical & regulatory experts to provide assistance & solutions to the varied needs of product development. D&BD is pleased to be associated with the following medical, regulatory and pharmaceutical experts.

Robert Bell, Ph.D.

Robert Bell, PHD

Dr. Robert Bell is a pharmaceutical executive with over 30 years of multidisciplinary experience in strategic global business development, product registration and commercialization of new drugs, biologics, devices and generic drug products. Bell has extensive experience with global business collaborations and product development efforts resulting in product approvals and market opportunities. Bell provides active leadership and mentoring involvement with pharmaceutical trade associations and academic institutions.

Bell’s employment history includes Vice President, New / Strategic Drug Development at Barr Laboratories, Inc., Vice President, Research, Development and Quality at Somerset Pharmaceuticals, Inc., Vice President, Research and Development at UDL Laboratories, Inc., Director, Research and Development at AL Pharma and Senior Chemist at Carter-Wallace, Inc. Bell’s research interests include pharmaceutical, clinical and biomedical analysis, CMC, quality, vaccines, follow-on proteins/biologics, treatment of drug addiction, women’s health and oncology therapeutics. Bell also serves as expert witness in pharmaceutical matters (e.g.GxPs, regulatory, product development, etc.).

Bell is an Affiliate Professor of Pharmacy at the College of Pharmacy at the Medical College of Virginia, Virginia Commonwealth University. Bell is also an Adjunct Professor of Pharmaceutics, a member of the National Advisory Board and recipient of the Distinguished Alumnus Award from the College of Pharmacy, University of Florida. Bell has published and presented extensively and has been issued eight patents and several are pending. Bell is the Past Chair of the Analysis and Pharmaceutical Quality (APQ) section for the American Association of Pharmaceutical Scientists (AAPS) and served in various leadership capacities for AAPS, including chair of the 2006 National Biotechnology Conference, Executive Council as Member-At-Large (2009), Chair of the Americas for the 2010 PSWC/AAPS Meeting and Chair of the AAPs Blog. Bell is a Member of the Council of Experts, General Chapters-Biological Analysis and the Joint Standards Subcommittee for United States Pharmacopeia, Editorial Advisory Board Member for the Journal of Chemical and Pharmaceutical Sciences and Enliven: Biosimilars and Bioavailability, and Co-Editor for the book Poorly Soluble Drugs: Dissolution and Drug Release.  Bell is a past Editorial Advisory Board Member for the Journal of Pharmaceutical and Biomedical Analysis, Editorial Advisory Board Member for the Journal of Chemical and Pharmaceutical Sciences and Expert Member, Board of Pharmaceutical Sciences, International Pharmaceutical Federation and reviewer for AAPS PharmSciTech. Bell is a member of the American Society of Clinical Oncology, American Urology Association, International Society of Andrology, American College of Clinical Pharmacology and American Chemical Society. Bell participates in the Visiting Scientist Program to universities, colleges and high schools.

Richard Lowenthal, M.S., M.S.E.L.

Mr. Richard Lowenthal is a pharmaceutical executive with over 25 years of Regulatory Affairs and Quality Assurance experience in various roles at both small and large pharmaceutical or biotechnology companies. Mr. Lowenthal has extensive experience with strategic global development as well as product registration of new drugs and biologics in the United States, Europe and Japan. Mr. Lowenthal has extensive experience with global business collaborations and evaluation of product licensing or investment opportunities. As founder of Pacific-Link Regulatory Consulting, Mr. Lowenthal is now dedicated to the support of pharmaceutical, biotechnology and investment companies, providing leadership and mentoring on Regulatory Affairs, Quality Assurance, Licensing and Investment opportunities.

Mr. Lowenthal has served as Vice President, Regulatory Affairs and Quality Assurance for Cadence Pharmaceuticals, Head of Worldwide Regulatory Affairs, Quality Assurance and Drug Safety for Maxim Pharmaceuticals, Inc., Vice President of Regulatory Affairs and Quality Assurance for AnGes, MG, Inc. (a Japanese based biopharmaceutical company), Global Project Leader and Global Director Regulatory Affairs for Janssen Research Foundation (a division of Johnson & Johnson), Director of Regulatory Affairs and Quality Assurance of Somerset Pharmaceuticals, Inc., and as a New Drug Review Chemist for the US Food and Drug Administration in the Division of Neuropharmacologic Drug Products and the Division of Oncology and Pulmonary Drug Products.

Mr. Lowenthal holds an M.S. in Organic Chemistry from FloridaStateUniversity and Masters in Business Science for Executive Leadership from the University of San Diego. Mr. Lowenthal has served as past Chair of the San Diego region for AAPS (2005/2006), as Member of the USP Biotechnology Expert Committee (2005/2006), Chair of the Virology Working group (2005/2006), Member of the National Organization of Rare Disease (NORD) Corporate Council (2002-Present), and several PhARMA and ICH Working Groups.

John Rapoza, M.S., R.Ph.

John R. Rapoza is a regulatory expert with over 30 years experience in drug development, clinical research, drug product registration and quality/regulatory compliance. Rapoza served as a senior executive for Drug Regulatory Affairs for Duramed, in Cincinnati; Wyeth-Ayerst in Philadelphia; Ayerst Laboratories in New York; Carter Wallace in Cranbury, New Jersey, Merrell Dow Pharmaceuticals in Indianapolis, and Dow Chemical in Midland, Michigan. Rapoza served on active duty with the U.S. Army Medical R&D Command where he was assigned Project Officer for the Army’s Investigational Drug Review Board. Rapoza earned his BS in Pharmacy from Massachusetts College of Pharmacy and MS in Pharmaceutical Sciences from Northeastern University and is board registered in Pharmacy in Massachusetts and Michigan.

Maria-Laura “Mimi” Ferraioli

Ms. Ferraioli brings over 20 years of experience as a Sales and Marketing Consultant for the pharmaceutical industry. Ferraioli graduated from St. Joseph’s University (BS Chemistry and Business Administration) and was employed in the biotechnology sector with BioWhittaker, Inc. and Baxter Healthcare, Inc. before starting her a sales and marketing consulting business.